Multiple studies demonstrated that PTK2 was overexpression and hyperphosphorylation in HCC [42–44], and the recent studies described that PTK2 activated CSC properties and tumorigenicity of HCC cells, leading to HCC recurrence and sorafenib resistance [44]. This evidence concerns the gene PTK2 and hepatocellular carcinoma.